Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that ... Russia , India and ... billion in 2013, roughly equal to the size of ... the BRIC market will experience much faster growth as a result ... population. Other key findings from Decision Resources Group,s coverage ...
(Date:8/20/2014)... in your ear could improve the health of your ... University of Leeds used a standard TENS machine like ... pulses to the tragus, the small raised flap at ... the ear canal. , The stimulation changed the influence ... the nervous signals that can drive failing hearts too ...
(Date:8/19/2014)... and Markets  has announced the addition of the "Cell and ... their offering. This report analyzes the worldwide markets ... following Product Segments: Media, Sera, and Reagents. The report ... , Japan , Europe , ... . Annual estimates and forecasts are provided for the period 2013 ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... SAN DIEGO, Nov. 20 Veridiam (www.veridiam.com) won the ... the 2009 Workplace Excellence Awards. The awards are sponsored ... and recognize innovative and exceptional human resources practices. , ... than 129 employee-nominated companies, honored at the recent awards ...
... ... webinar, “Roller Compactions Process Optimization Using At-Line Particle Characterization”, will be presented on December ... demonstrated to map the design space and optimize a series of roller compaction runs ... ...
... Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, ... Biropharma Kft, discrediting the Hungarian company for making false and ... Dr. Hidvegi stated from his office in Budapest, Hungary: ... apply to AveULTRA, www.aveultra.com , is misleading. ...
Cached Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... one day be made out of cocoa, rice and ... The novel process they developed and their results, which ... plastic waste problems, appear in the ACS journal ... colleagues at the Italian Institute of Technology point out ... production reached 288 million tons worldwide, but its ubiquity ...
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3Research paves way for development of cyborg moth 'biobots' 2
... Research Institute is reporting a discovery that sheds light ... the normal processes that govern the everyday life of ... diseases, including cancer and septic shock. , The discovery ... their relationship to the genetic transcripts known as messenger ...
... to fathom a proverb ?catch the figurative meaning of "an ... research led by V. S. Ramachandran, director of the Center ... Diego, a region of the brain known as the angular ... ability to understand metaphor. , Ramachandran and colleagues tested four ...
... by a team of researchers at Penn State, which also ... to control tissue growth. The team's genetic and biochemical studies ... the journal Cell. "This discovery extends our understanding of how ... the formation of tumors, and it raises the possibility that ...
Cached Biology News:Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 2Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 3Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 4Grasping metaphors: UC San Diego research ties brain area to figures of speech 2New tumor-suppressor gene discovered 2New tumor-suppressor gene discovered 3New tumor-suppressor gene discovered 4
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Biology Products: